Bronchopulmonary dysplasia: Biomarkers, lung function, and clinical course

The paper presents an investigation of airway resistance with bronchodilator response and time course of changes in the levels of proinflammatory (IL-1β) and anti-inflammatory (IL-4, IL-10) cytokines and the indirect marker of fibrosis — matrix metalloproteinase 3 (MMP3) in order to specify their role in the immunopathogenesis and course of bronchopulmonary dysplasia. 15 healthy full-term infants aged 3 to 20 months and 39 premature infants (a study group) with bronchopulmonary dysplasia were examined. The infants of the study group were divided into 3 subgroups: 1) 11 babies of less than 55 weeks postconceptual age; 2) 11 infants of 55–75 weeks postconceptual age; 3) 17 ones of 76–141 weeks conceptual age. Airway resistance and bronchodilator response were investigated using the Rint method; oxygen saturation and the presence of RS virus in nasal secretions were determined. An enzyme immunoassay was used to estimate the blood levels of IL-1β, IL-4, IL-10, and MMP3. It was ascertained that the increased level of IL-10 were more common in Subgroup 1 and that of MMP3 in Subgroup 2 as compared to the group of healthy infants. As this takes place, a 10‑fold and more increase in IL-10 levels in the infants from Group 3 (the old group) is a poor prognostic factor. The infants in Subgroups 1 and 2 showed higher Rint and more marked bronchodilator response, suggesting respiratory failure. Conclusions. As the infant grows, there are decreases in the frequency of exacerbations and in the magnitude of bronchodilator response and an increase in saturation, but the proportion of infants with greater responsiveness remains high and fails to reach the values observed in healthy babies. Immunological heterogeneity and mosaicism of changes in the levels of biomarkers of bronchopulmonary dysplasia suggest that there may be different inflammatory phenotypes in this disease.

1. Chess P. R., D'Angio C. T., Pryhuber G. S. et al. Pathogenesis of bronchopulmonary dysplasia. Semin Perinatol 2006; 30: 4: 171–178.

2. Mosca F., Colnaghi M., Fumagalli M. BPD: old and new problems. J Matern Fetal Neonatal Med 2011; 24: 1: 80–82.

3. Батман Ю. А., Натрус Л. В., Павлюченко В. В. и др. Изучение патогенетических механизмов формирования иммунного ответа у недоношенных детей с бронхолегочной дисплазией. Медико-социальные проблемы семьи 2013; 18: 2: 73–80. (Batman Ju. A., Natrus L. V., Pavljuchenko V. V. et al. Study of pathogenetic mechanisms of immunological response in preterm infants with bronchopulmonary dysplasia. Mediko- sotsial’nye problemy sem'i 2013; 18: 2: 73–80.)

4. Павлов К. А., Дубова Е. А., Мишнёв О. Д. и др. Медиаторные взаимодействия при остром респираторном дистресссиндроме. Общая реаниматология 2007; 3: 5–6: 208– 212. (Pavlov K. A., Dubova Ye. A., Mishnyov O. D. et al. Mediator interactions in acute Respiratory Distress Syndrome. Obshhaya reanimatologiya 2007; 3: 5–6: 208–212.)

5. Железникова Г. Ф. Цитокины как предикторы течения и исхода инфекций. Цитокины и воспаление 2009; 8: 1: 10–17. (Zheleznikova G. F. Cytokines as predictors of the course and outcome of infections. TSitokiny i vospalenie 2009; 8: 1: 10–17.)

6. Bhandari A., Bhandari V. Biomarkers in Bronchopulmonary Dysplasia. Paediatric Respiratory Reviews 2013; 14: 3: 173–179.

7. Ambalavanan N., Carlo W. A., D'Angio C. T. et al. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics 2009; 123: 4: 1132–1141.

8. Koksal N., Kayik B., Cetinkaya M. et al. Value of serum and bronchoalveolar fluid lavage pro- and anti-inflammatory cytokine levels for predicting bronchopulmonary dysplasia in premature infants. Eur Cytokine Netw 2012; 23: 2: 29–35.

9. Лебедева О. В. Факторы риска формирования бронхолегочной дисплазии у новорожденных с очень низкой и экстремально низкой массой тела при рождении. Педиатр фармакол 2014; 11: 3: 37–42. (Lebedeva O. V. Risk factors of bronchopulmonary dysplasia in infants with very low and extremely low body weight at birth. Pediatr farmakol 2014; 11: 3: 37–42.)

10. Панченко А. С., Гаймоленко И. Н., Игнатьева А. В. Бронхолегочная дисплазия у детей: факторы риска и иммунобиохимические маркеры. Пульмонология 2015; 1: 86–92.

11. (Panchenko A. S., Gaymolenko I. N., Ignateva A. V. Bronchopulmonary dysplasia in children: risk factors, immunological and biochemical markers. Pul'monologiya 2015; 1: 86–92.)

12. Greenlee K. J., Werb Z., Kheradmand F. Matrix Metalloproteinases in Lung: Multiple, Multifarious, and Multifaceted. Physiol Rev 2007; 87: 69–98.

13. Piesiak P., Kraus–Filarska M., Kosacka M. et al. The Role of Metalloproteinases in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Adv Clin Exp Med 2009; 18: 3: 303–309.

14. Турна А. А., Тогузов Р. Т. Матриксные металлопротеиназы и сердечно-сосудистые заболевания. Артериальная гипертензия 2009; 15: 5: 532–538. (Turna A. A., Toguzov R. T. Matrix metalloproteinases and cardiovascular diseases. Аrterial’naya gipertenziya 2009; 15: 5: 532–538.)

15. Vento G., Tirone Ch., Lulli P. et al. Bronchoalveolar lavage fluid peptidomics suggests a possible matrix metalloproteinase-3 role in bronchopulmonary dysplasia. Intensive Care Medicine 2009; 35: 12: 2115–2124.

16. Shaw G. M., O’Brodovich H. M. Progress in understanding the genetics of bronchopulmonary dysplasia. Semin Perinatol 2013; 37: 85–93.

17. Давыдова И. В., Намазова-Баранова Л. С., Алтунин В. В. и др. Функциональная оценка респираторных нарушений у детей с бронхолегочной дисплазией при катамнестическом наблюдении. Педиатр фармакол 2014; 11: 6: 42–51. (Davydova I. V., Namazova-Baranova L. S., Altunin V. V. et al. Functional assessment of respiratory disorders in children with bronchopulmonary dysplasia during followup. Pediatr farmakol 2014; 11: 6: 42–51.)

18. Научно-практическая программа «Бронхолегочная дисплазия». М.: Оригинал- маркет, 2012; 88. (Scientific and practical program «Bronchopulmonary dysplasia». Moscow: Original-market, 2012; 88.)

19. Wright C. J. Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies? Pediatrics 2011; 128: 111–126.